Terns Pharmaceuticals, Inc.
TERN
$2.92
-$0.13-4.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -21.80M | -21.95M | -22.74M | -22.37M | -21.02M |
| Total Depreciation and Amortization | 214.00K | 206.00K | 240.00K | 236.00K | 220.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.78M | 4.19M | 3.89M | 3.70M | 1.64M |
| Change in Net Operating Assets | 5.22M | 1.10M | 2.43M | -4.36M | -161.00K |
| Cash from Operations | -14.58M | -16.46M | -16.18M | -22.80M | -19.32M |
| Capital Expenditure | 0.00 | 0.00 | -13.00K | -29.00K | -44.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -94.35M | 31.75M | 42.20M | 8.03M | 47.28M |
| Cash from Investing | -94.35M | 31.75M | 42.19M | 8.00M | 47.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 617.00K | 163.37M | 399.00K | -- | 13.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -313.00K | -75.00K | -- | -- | 0.00 |
| Cash from Financing | 304.00K | 163.29M | 399.00K | -- | 13.86M |
| Foreign Exchange rate Adjustments | -69.00K | 53.00K | -14.00K | -26.00K | 255.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.70M | 178.64M | 26.40M | -14.83M | 42.03M |